GW Pharmaceuticals ROE 2013-2018 | GWPH

Current and historical return on equity (ROE) values for GW Pharmaceuticals (GWPH) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. GW Pharmaceuticals ROE for the three months ending September 30, 2018 was -55.88%.
GW Pharmaceuticals ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $-0.19B $0.00B -44.50%
2018-06-30 $-0.19B $0.50B -44.50%
2018-03-31 $-0.20B $0.56B -51.10%
2017-12-31 $-0.16B $0.62B -42.93%
2017-09-30 $-0.11B $0.00B -34.26%
2017-06-30 $-0.11B $0.41B -34.26%
2017-03-31 $-0.08B $0.44B -26.15%
2016-12-31 $-0.06B $0.48B -22.33%
2016-09-30 $-0.07B $0.00B -28.70%
2016-06-30 $-0.07B $0.27B -28.70%
2016-03-31 $-0.05B $0.31B -30.91%
2015-12-31 $-0.03B $0.34B -30.68%
2015-09-30 $0.00B $0.00B nan%
2015-06-30 $0.00B $0.00B nan%
2015-03-31 $0.00B $0.00B nan%
2014-12-31 $0.00B $0.00B nan%
2014-09-30 $0.00B $0.00B nan%
2014-06-30 $0.00B $0.00B nan%
2014-03-31 $0.00B $0.00B nan%
2013-12-31 $0.00B $0.00B nan%
2013-09-30 $0.00B $0.00B nan%
2013-06-30 $0.00B $0.00B nan%
2013-03-31 $0.00B $0.00B nan%
2012-12-31 $0.00B $0.00B nan%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $4.900B $0.013B
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $137.198B 26.75
Medtronic (MDT) Ireland $116.492B 17.03
Stryker (SYK) United States $69.834B 24.92
Boston Scientific (BSX) United States $51.351B 24.62
Baxter (BAX) United States $38.973B 24.52
Zimmer Biomet Holdings (ZBH) United States $25.515B 16.33
Smith & Nephew SNATS (SNN) United Kingdom $16.913B 0.00
Canopy Growth (CGC) Canada $16.587B 0.00
ResMed (RMD) United States $14.652B 27.78
Aurora Cannabis (ACB) Canada $9.189B 64.79
Bio-Rad Laboratories (BIO) United States $8.907B 51.09
Perrigo (PRGO) Ireland $6.811B 11.04
Hill-Rom Holdings (HRC) United States $6.475B 20.03
Insulet (PODD) United States $4.964B 1664.00
ICU Medical (ICUI) United States $4.648B 28.79
Haemonetics (HAE) United States $4.345B 38.54
Hutchison China MediTech (HCM) China $3.899B 0.00
Agios Pharmaceuticals (AGIO) United States $3.354B 0.00
NuVasive (NUVA) United States $3.069B 26.66
Neogen (NEOG) United States $3.016B 49.04
Quidel (QDEL) United States $2.490B 22.28
National Vision Holdings (EYE) United States $2.281B 44.86
Aphria (APHA) $1.919B 0.00
HEXO (HEXO) $1.510B 0.00
Phibro Animal Health (PAHC) United States $1.352B 19.44
Cardiovascular Systems (CSII) United States $1.222B 877.50
VAREX IMAGING (VREX) United States $1.214B 23.77
AtriCure (ATRC) United States $1.089B 0.00
Lantheus Holdings (LNTH) United States $0.960B 25.95
Omeros (OMER) United States $0.920B 0.00
PetIQ (PETQ) United States $0.871B 24.92
Cerus (CERS) United States $0.823B 0.00
MacroGenics (MGNX) United States $0.813B 0.00
NanoString Technologies (NSTG) United States $0.787B 0.00
Evolus (EOLS) United States $0.756B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.734B 24.99
TG Therapeutics (TGTX) United States $0.712B 0.00
OraSure Technologies (OSUR) United States $0.591B 25.76
LeMaitre Vascular (LMAT) United States $0.569B 27.03
Surmodics (SRDX) United States $0.567B 82.39
Meridian Bioscience (VIVO) United States $0.550B 16.38
Quanterix (QTRX) United States $0.492B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.320B 0.00
Utah Medical Products (UTMD) United States $0.317B 21.92
Insys Therapeutics (INSY) United States $0.314B 0.00
BioLife Solutions (BLFS) United States $0.308B 127.08
Vapotherm (VAPO) United States $0.293B 0.00
Rockwell Medical (RMTI) United States $0.267B 0.00
Cytosorbents (CTSO) United States $0.229B 0.00
Owens & Minor (OMI) United States $0.216B 2.96
Zynex (ZYXI) United States $0.174B 18.59
Bovie Medical (APYX) United States $0.161B 0.00
Fonar (FONR) United States $0.130B 6.96
Chimerix (CMRX) United States $0.129B 0.00
Chembio Diagnostics (CEMI) United States $0.125B 0.00
Surface Oncology (SURF) United States $0.112B 0.00
United-Guardian (UG) United States $0.089B 20.32
InfuSystems Holdings (INFU) United States $0.086B 0.00
Female Health (VERU) United States $0.085B 0.00
Neurotrope (NTRP) United States $0.076B 0.00
Trinity Biotech (TRIB) Ireland $0.067B 19.79
Oramed Pharmaceuticals (ORMP) United States $0.066B 0.00
ImmuCell (ICCC) United States $0.046B 0.00
GUARDION HEALTH (GHSI) United States $0.045B 0.00
Senestech (SNES) United States $0.036B 0.00
Valeritas Holdings (VLRX) United States $0.031B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.023B 0.00
Myomo (MYO) United States $0.020B 0.00
Capricor Therapeutics (CAPR) United States $0.017B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.013B 0.00
Cellectar Biosciences (CLRB) United States $0.012B 0.00
Akers Biosciences Inc (AKER) United States $0.010B 0.00
NeuroMetrix (NURO) United States $0.006B 5.87